



Liletta[®] (levonorgestrel-releasing intrauterine system) – Expanded indication

- On August 3, 2017, the [FDA approved](#) Allergan/Medicines360's [Liletta \(levonorgestrel-releasing intrauterine system\)](#) for prevention of pregnancy for up to 4 years. The system should be replaced after 4 years if continued use is desired.
 - Previously, Liletta was approved for use for up to 3 years.
- Liletta's expanded indication is based on data from a clinical study which demonstrated a pregnancy rate of 0.13% (95% CI: 0.00, 0.74) during year 4 of Liletta use.
- Liletta is an intrauterine system containing 52 mg of levonorgestrel. It must be inserted by a trained healthcare provider using strict aseptic technique. Liletta can be removed at any time but must be removed by the end of the fourth year.
- Other currently available levonorgestrel-releasing intrauterine systems used for pregnancy prevention include [Kyleena[®]](#), [Mirena[®]](#), and [Skyla[®]](#).
 - Kyleena and Mirena are approved for use for up to 5 years. Skyla is approved for use for up to 3 years.
 - Mirena is also indicated for the treatment of heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.